Format

Send to

Choose Destination
Cancer Cell. 2002 Feb;1(1):31-6.

Perspectives on the development of a molecularly targeted agent.

Author information

1
Leukemia Center, Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Road, Portland 97201, USA. drukerb@ohsu.edu

Abstract

STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.

PMID:
12086885
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center